Collegium Pharmaceutical, Inc. (NASDAQ: COLL) Receives Analysts’ Average “Moderate Buy” Recommendation

Collegium Pharmaceutical, Inc. (NASDAQ: COLL – Get a rating) received an average “moderate buy” rating from the six brokerages that cover the stock, MarketBeat reports. Two research analysts rated the stock with a hold recommendation and three gave the company a buy recommendation. The 12-month average price target among analysts who have rated the stock over the past year is $34.67.

COLL has been the subject of several analyst reports. HC Wainwright downgraded shares of Collegium Pharmaceutical to a “neutral” rating in a Monday, August 15 report. StockNews.com downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a Thursday, May 19 report.

Performance of Collegium Pharmaceutical shares

COLL opened at $17.34 on Friday. The company has a current ratio of 0.99, a quick ratio of 0.80 and a debt ratio of 3.16. The company’s fifty-day moving average price is $17.88 and its two-hundred-day moving average price is $17.63. Collegium Pharmaceutical has a 1-year low of $14.04 and a 1-year high of $22.89. The company has a market capitalization of $591.74 million, a price-earnings ratio of -16.51, a PEG ratio of 0.20 and a beta of 0.86.

A d Legacy search

This little-known financial ‘hack’ could forever change the way Americans shop

The Financial Genius reveals how to buy anything you want – without paying as usual.

Collegium Pharmaceutical (NASDAQ: COLL- Get a rating) last released its quarterly earnings data on Thursday, August 4. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $1.15 per ($1.19). Collegium Pharmaceutical had a negative return on equity of 2.12% and a negative net margin of 11.24%. The company posted revenue of $123.55 million for the quarter, versus analyst estimates of $122.63 million. On average, analysts expect Collegium Pharmaceutical to post EPS of 4.21 for the current fiscal year.

Collegium Pharmaceutical Institutional Trading

Institutional investors and hedge funds have recently changed their positions in the company. Mutual of America Capital Management LLC increased its position in Collegium Pharmaceutical by 14.6% during the second quarter. Mutual of America Capital Management LLC now owns 5,706 shares of the specialty pharmaceutical company valued at $101,000 after purchasing an additional 725 shares during the period. Bank of Montreal Can increased its position in Collegium Pharmaceutical by 9.2% during the first quarter. Bank of Montreal Can now owns 11,850 shares of the specialty pharmaceutical company valued at $239,000 after purchasing an additional 1,001 shares during the period. Captrust Financial Advisors increased its position in Collegium Pharmaceutical by 97.5% during the first quarter. Captrust Financial Advisors now owns 2,151 shares of the specialty pharmaceutical company valued at $44,000 after purchasing an additional 1,062 shares during the period. Rhumbline Advisers increased its position in Collegium Pharmaceutical by 1.3% during the fourth quarter. Rhumbline Advisers now owns 90,715 shares of the specialty pharmaceutical company valued at $1,695,000 after purchasing an additional 1,159 shares during the period. Finally, Denali Advisors LLC increased its position in Collegium Pharmaceutical by 76.5% during the second quarter. Denali Advisors LLC now owns 3,000 shares of the specialty pharmaceutical company valued at $53,000 after purchasing an additional 1,300 shares during the period.

About Collegium Pharmaceutical

(Get a rating)

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets drugs for pain management. Its portfolio includes Xtampza ER, an oral, extended-release, abuse-deterrent oxycodone formulation; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid therapy.

Recommended Stories

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Collegium Pharmaceutical, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Collegium Pharmaceutical didn’t make the list.

While Collegium Pharmaceutical currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here